Top

Published in:

01-05-2017

Prophylactic implantable cardioverter defibrillator in heart failure: the growing evidence for all or Primum non nocere for some?

Authors: Khang-Li Looi, Nigel Lever, Anthony Tang, Sharad Agarwal

Published in: Heart Failure Reviews | Issue 3/2017

Abstract

Heart failure (HF) is a common health problem and has reached epidemic in many western countries. Despite the current era of HF treatment, the risk of sudden cardiac death (SCD) in HF remains significant. Implantable cardioverter defibrillator (ICD) support has been shown to reduce the risk of SCD in patients with HF and impaired left ventricular function. Prophylactic ICD implantation in HF patients seems a logical step to reduce mortality through a reduction in SCD. However, ICD implantation is an invasive procedure, and both short- and long-term complications can occur. This needs to be carefully considered when evaluating the risk-benefit ratio of ICD implantation for individual patients. As the severity of HF increases, the proportion of SCD compared with HF-related deaths decreases. The challenge lies in identifying patients with HF who are at significant risk of SCD and who would most benefit from an ICD in addition to other anti-arrhythmic strategies. This review offers insight on the applicability and practicability of ICD for this growing population.

Mosterd A, Hoes AW (2007) Clinical epidemiology of heart failure. Heart 93(9):1137–1146PubMedPubMedCentralCrossRef

Wasywich CA, Gamble GD, Whalley GA, Doughty RN (2010) Understanding changing patterns of survival and hospitalization for heart failure over two decades in New Zealand: utility of ‘days alive and out of hospital’ from epidemiological data. Eur J Heart Fail 12(5):462–468PubMedCrossRef

Jhund PS, MacIntyre K, Simpson CR, Lewsey JD, Stewart S, Redpath A et al (2009) Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003. A population study of 51 million people. Circulation 119(4):515–523PubMedCrossRef

Schaufelberger M, Swedberg K, Köster M, Rosén M, Rosengren A. (2004) Decreasing one-year mortality and hospitalization rates for heart failure in Sweden. Data from the Swedish Hospital Discharge Registry 1988 to 2000. 25(4):300–307

Shafazand M, Schaufelberger M, Lappas G, Swedberg K, Rosengren A (2009) Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987–2003 from the Swedish Hospital Discharge Registry. Eur Heart J 30(6):671–678PubMedCrossRef

McLean AS, Eslick GD, Coats AJS (2007) The epidemiology of heart failure in Australia. Int J Cardiol 118(3):370–374PubMedCrossRef

Cupples LA, Gagnon DR, Kannel WB (1992) Long- and short-term risk of sudden coronary death. Circulation 85(1 Suppl):I11–I18PubMed

Deo R, Albert CM (2012) Epidemiology and genetics of sudden cardiac death. Circulation 125(4):620–637PubMedPubMedCentralCrossRef

Singh SN, Carson PE, Fisher SG (1997) Nonsustained ventricular tachycardia in severe heart failure. Circulation 96(10):3794–3795PubMed

10.

Goldberger JJ, Buxton AE, Cain M, Costantini O, Exner DV, Knight BP et al (2011) Risk stratification for arrhythmic sudden cardiac death: identifying the roadblocks. Circulation 123(21):2423–2430PubMedCrossRef

11.

Gorgels APM, Gijsbers C, de Vreede-Swagemakers J, Lousberg A, Wellens HJJ (2003) Out-of-hospital cardiac arrest-the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart J 24(13):1204–1209PubMedCrossRef

12.

Stecker EC, Vickers C, Waltz J, Socoteanu C, John BT, Mariani R et al (2006) Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol 47(6):1161–1166PubMedCrossRef

13.

Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G (1999) A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 341(25):1882–1890PubMedCrossRef

14.

Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H et al (1996) Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 335(26):1933–1940PubMedCrossRef

15.

Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346(12):877–883PubMedCrossRef

16.

Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352(3):225–237PubMedCrossRef

17.

Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS et al (2013) 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 127(3):e283–e352PubMedCrossRef

18.

Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS et al (2000) Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 101(11):1297–1302PubMedCrossRef

19.

The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators (1997) A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 337(22):1576–1584CrossRef

20.

Ezekowitz JA, Rowe BH, Dryden DM, Hooton N, Vandermeer B, Spooner C et al (2007) Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med 147(4):251–262PubMedCrossRef

21.

Ezzat VA, Lee V, Ahsan S, Chow AW, Segal O, Rowland E et al (2015) A systematic review of ICD complications in randomised controlled trials versus registries: is our ‘real-world’ data an underestimation? Open Heart 2(1):e000198PubMedPubMedCentralCrossRef

22.

Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP et al (2004) Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350(21):2151–2158PubMedCrossRef

23.

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62(16):e147–e239PubMedCrossRef

24.

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 18(8):891–975PubMedCrossRef

25.

Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E et al (2016) Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 375(13):1221–1230PubMedCrossRef

26.

Cheng S, Larson MG, Keyes MJ, McCabe EL, Newton-Cheh C, Levy D et al (2010) Relation of QRS width in healthy persons to risk of future permanent pacemaker implantation. Am J Cardiol 106(5):668–672PubMedPubMedCentralCrossRef

27.

Eriksson P, Hansson PO, Eriksson H, Dellborg M (1998) Bundle-branch block in a general male population: the study of men born 1913. Circulation 98(22):2494–2500PubMedCrossRef

28.

Imanishi R, Seto S, Ichimaru S, Nakashima E, Yano K, Akahoshi M (2006) Prognostic significance of incident complete left bundle branch block observed over a 40-year period. Am J Cardiol 98(5):644–648PubMedCrossRef

29.

Rautaharju PM, Ge S, Nelson JC, Marino Larsen EK, Psaty BM, Furberg CD et al (2006) Comparison of mortality risk for electrocardiographic abnormalities in men and women with and without coronary heart disease (from the Cardiovascular Health Study). Am J Cardiol 97(3):309–315PubMedCrossRef

30.

Lund LH, Jurga J, Edner M, Benson L, Dahlström U, Linde C et al (2013) Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. Eur Heart J 34(7):529–539PubMedCrossRef

31.

Abdel-Qadir HM, Tu JV, Austin PC, Wang JT, Lee DS (2011) Bundle branch block patterns and long-term outcomes in heart failure. Int J Cardiol 146(2):213–218PubMedCrossRef

32.

Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E et al (2002) Cardiac resynchronization in chronic heart failure. N Engl J Med 346(24):1845–1853PubMedCrossRef

33.

Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B et al (2003) Combined cardiac resynchronization and implantable Cardioversion defibrillation in advanced chronic heart failure. JAMA 289(20):2685–2694PubMedCrossRef

34.

Higgins SL, Hummel JD, Niazi IK, Giudici MC, Worley SJ, Saxon LA et al (2003) Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 42(8):1454–1459PubMedCrossRef

35.

Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L et al (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352(15):1539–1549PubMedCrossRef

36.

Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T et al (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350(21):2140–2150PubMedCrossRef

37.

Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA et al (2013) 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace 15(8):1070–1118PubMedCrossRef

38.

Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP et al (2009) Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361(14):1329–1338PubMedCrossRef

39.

Tang ASL, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S et al (2010) Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 363(25):2385–2395PubMedCrossRef

40.

Santangeli P, Di Biase L, Pelargonio G, Dello Russo A, Casella M, Bartoletti S et al (2011) Cardiac resynchronization therapy in patients with mild heart failure: a systematic review and meta-analysis. J Interv Card Electrophysiol 32(2):125–135PubMedCrossRef

41.

Lindenfeld J, Feldman AM, Saxon L, Boehmer J, Carson P, Ghali JK et al (2007) Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York heart association class IV heart failure. Circulation 115(2):204–212PubMedCrossRef

42.

Looi KL, Gajendragadkar PR, Khan FZ, Elsik M, Begley DA, Fynn SP et al (2014) Cardiac resynchronisation therapy: pacemaker versus internal cardioverter-defibrillator in patients with impaired left ventricular function. Heart 100(10):794–799PubMedCrossRef

43.

Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH et al (2008) Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 359(10):1009–1017PubMedPubMedCentralCrossRef

44.

Thijssen J, van Rees JB, Venlet J, Borleffs CJW, Höke U, Putter H et al (2012) The mode of death in implantable cardioverter-defibrillator and cardiac resynchronization therapy with defibrillator patients: results from routine clinical practice. Heart Rhythm 9(10):1605–1612PubMedCrossRef

45.

Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H et al (2008) Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 51(3):288–296PubMedCrossRef

46.

Barra S, Looi K-L, Gajendragadkar PR, Khan FZ, Virdee M, Agarwal S. (2015) Applicability of a risk score for prediction of the long-term benefit of the implantable cardioverter defibrillator in patients receiving cardiac resynchronization therapy. Europace

47.

Marijon E, Leclercq C, Narayanan K, Boveda S, Klug D, Lacaze-Gadonneix J et al (2015) Causes-of-death analysis of patients with cardiac resynchronization therapy: an analysis of the CeRtiTuDe cohort study. Eur Heart J 36(41):2767–2776PubMedPubMedCentralCrossRef

48.

Carson P, Anand I, O'Connor C, Jaski B, Steinberg J, Lwin A et al (2005) Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol 46(12):2329–2334PubMedCrossRef

49.

Barsheshet A, Goldenberg I, Moss AJ, Eldar M, Huang DT, McNitt S et al (2011) Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT. Eur Heart J 32(13):1622–1630PubMedCrossRef

50.

Goldenberg I, Moss AJ, Hall WJ, Foster E, Goldberger JJ, Santucci P et al (2011) Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 124(14):1527–1536PubMedCrossRef

51.

Hsu JC, Solomon SD, Bourgoun M, McNitt S, Goldenberg I, Klein H et al (2012) Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study. J Am Coll Cardiol 59(25):2366–2373PubMedCrossRef

52.

Schuchert A, Muto C, Maounis T, Frank R, Boulogne E, Polauck A et al (2013) Lead complications, device infections, and clinical outcomes in the first year after implantation of cardiac resynchronization therapy-defibrillator and cardiac resynchronization therapy-pacemaker. Europace 15(1):71–76PubMedCrossRef

53.

Eckstein J, Koller MT, Zabel M, Kalusche D, Schaer BA, Osswald S et al (2008) Necessity for surgical revision of defibrillator leads implanted long-term. Causes and Management 117(21):2727–2733

54.

Maisel WH, Kramer DB (2008) Implantable cardioverter-defibrillator lead performance. Circulation 117(21):2721–2723PubMedCrossRef

55.

Hauser RG, Katsiyiannis WT, Gornick CC, Almquist AK, Kallinen LM (2010) Deaths and cardiovascular injuries due to device-assisted implantable cardioverter–defibrillator and pacemaker lead extraction. Europace 12(3):395–401PubMedCrossRef

56.

Gasparini M, Regoli F, Galimberti P, Ceriotti C, Cappelleri A (2009) Cardiac resynchronization therapy in heart failure patients with atrial fibrillation. Europace 11(suppl 5):v82–vv6PubMedPubMedCentralCrossRef

57.

Gasparini M, Auricchio A, Metra M, Regoli F, Fantoni C, Lamp B et al (2008) Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J 29(13):1644–1652PubMedPubMedCentralCrossRef

58.

Alam MB, Munir MB, Rattan R, Flanigan S, Adelstein E, Jain S et al (2014) Battery longevity in cardiac resynchronization therapy implantable cardioverter defibrillators. Europace 16(2):246–251PubMedCrossRef

59.

Uslan DZ, Gleva MJ, Warren DK, Mela T, Chung MK, Gottipaty V et al (2012) Cardiovascular implantable electronic device replacement infections and prevention: results from the REPLACE registry. Pacing Clin Electrophysiol 35(1):81–87PubMedCrossRef

60.

Johansen JB, Jørgensen OD, Møller M, Arnsbo P, Mortensen PT, Nielsen JC (2011) Infection after pacemaker implantation: infection rates and risk factors associated with infection in a population-based cohort study of 46299 consecutive patients. Eur Heart J 32(8):991–998PubMedPubMedCentralCrossRef

61.

Poole JE, Gleva MJ, Mela T, Chung MK, Uslan DZ, Borge R, et al. (2010) Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures. Results from the REPLACE Registry. 122(16):1553–1561

62.

Koelling TM, Chen RS, Lubwama RN, L'Italien GJ, Eagle KA (2004) The expanding national burden of heart failure in the United States: the influence of heart failure in women. Am Heart J 147(1):74–78PubMedCrossRef

63.

Rathore SS, Foody JM, Wang Y, Herrin J, Masoudi FA, Havranek EP et al (2005) Sex, quality of care, and outcomes of elderly patients hospitalized with heart failure: findings from the National Heart Failure Project. Am Heart J 149(1):121–128PubMedPubMedCentralCrossRef

64.

Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB et al (2012) Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation 125(1):e2–e220PubMedCrossRef

65.

Agvall B, Dahlstrom U (2001) Patients in primary health care diagnosed and treated as heart failure, with special reference to gender differences. Scand J Prim Health Care 19(1):14–19PubMedCrossRef

66.

Heiat A, Gross CP, Krumholz HM (2002) Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 162(15):1682–1688PubMedCrossRef

67.

Buxton AE, Lee KL, DiCarlo L, Gold MR, Greer GS, Prystowsky EN et al (2000) Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. N Engl J Med 342(26):1937–1945PubMedCrossRef

68.

Xu Y-Z, Friedman PA, Webster T, Brooke K, Hodge DO, Wiste HJ et al (2012) Cardiac resynchronization therapy: do women benefit more than men? J Cardiovasc Electrophysiol 23(2):172–178PubMedCrossRef

69.

Leyva F, Foley PWX, Chalil S, Irwin N, Smith REA (2011) Female gender is associated with a better outcome after cardiac resynchronization therapy. Pacing Clin Electrophysiol 34(1):82–88PubMedCrossRef

70.

Sipahi I, Chou JC, Hyden M, Rowland DY, Simon DI, Fang JC (2012) Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Am Heart J 163(2):260–7.e3PubMedPubMedCentralCrossRef

71.

Sipahi I, Fang JC (2013) QRS duration criteria to select patients for cardiac resynchronization therapy: CRT should Be reserved for a QRS duration ≥150 ms: Pro. Circulation: Arrhythmia and Electrophysiology 6(2):436–442

72.

Zusterzeel R, Curtis JP, Caños DA, Sanders WE, Selzman KA, Piña IL et al (2014) Sex-specific mortality risk by QRS morphology and duration in patients receiving CRT: results from the NCDR. J Am Coll Cardiol 64(9):887–894PubMedCrossRef

73.

Zusterzeel R, Selzman KA, Sanders WE et al (2014) Cardiac resynchronization therapy in women: us food and drug administration meta-analysis of patient-level data. JAMA Intern Med 174(8):1340–1348PubMedCrossRef

74.

Barra S, Providência R, Duehmke R, et al. Sex-specific outcomes with addition of defibrillation to resynchronisation therapy in patients with heart failureHeart Published Online First: 19 January 2017. doi:10.1136/heartjnl-2016-310677

75.

Jacobs AK (2003) Coronary revascularization in women in 2003: sex revisited. Circulation 107(3):375–377PubMedCrossRef

76.

Lichtman JH, Wang Y, Jones SB, Leifheit-Limson EC, Shaw LJ, Vaccarino V et al (2014) Age and sex differences in inhospital complication rates and mortality after percutaneous coronary intervention procedures: evidence from the NCDR((R)). Am Heart J 167(3):376–383PubMedCrossRef

77.

Reynolds MR, Cohen DJ, Kugelmass AD, Brown PP, Becker ER, Culler SD et al (2006) The frequency and incremental cost of major complications among Medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol 47(12):2493–2497PubMedPubMedCentralCrossRef

78.

Peterson PN, Daugherty SL, Wang Y, Vidaillet HJ, Heidenreich PA, Curtis JP et al (2009) Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defibrillator therapy. Circulation 119(8):1078–1084PubMedCrossRef

79.

Russo AM, Daugherty SL, Masoudi FA, Wang Y, Curtis J, Lampert R (2015) Gender and outcomes after primary prevention implantable cardioverter-defibrillator implantation: findings from the National Cardiovascular Data Registry (NCDR). Am Heart J 170(2):330–338PubMedPubMedCentralCrossRef

80.

Ranasinghe I, Parzynski CS, Freeman JV, Dreyer RP, Ross JS, Akar JG et al (2016) Long-term risk for device-related complications and reoperations after implantable cardioverter-defibrillator implantation: an observational cohort study. Ann Intern Med 165(1):20–29

81.

Kannel WB, Schatzkin A (1985) Sudden death: lessons from subsets in population studies. J Am Coll Cardiol 5(6 Suppl):141B–149BPubMedCrossRef

82.

Rho RW, Patton KK, Poole JE, Cleland JG, Shadman R, Anand I et al (2012) Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillator. Circulation 126(20):2402–2407PubMedCrossRef

83.

Stewart GC, Chen C-Y, Stevenson LW, Williams L, Seeger J, Jalbert J et al (2013) Outcomes among Medicare beneficiaries are optimized when primary ICD implant occurs during an elective rather than unplanned hospitalization. Circulation 128:A11117

84.

U.S. Census Bureau (2014) An aging nation: the older population in the United States www.census.gov/popest

85.

Huang DT, Sesselberg HW, McNitt S, Noyes K, Andrews ML, Hall WJ et al (2007) Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy. J Cardiovasc Electrophysiol 18(8):833–838PubMedCrossRef

86.

Santangeli P, Di Biase L, Dello Russo A, Casella M, Bartoletti S, Santarelli P et al (2010) Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators. Ann Intern Med 153(9):592–599PubMedCrossRef

87.

Lee DS, Tu JV, Austin PC, Dorian P, Yee R, Chong A et al (2007) Effect of cardiac and noncardiac conditions on survival after defibrillator implantation. J Am Coll Cardiol 49(25):2408–2415PubMedCrossRef

88.

Expósito V, Rodríguez-Mañero M, González-Enríquez S, Arias MA, Sánchez-Gómez JM, Andrés La Huerta A, et al. (2015) Primary prevention implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator in elderly patients: results of a Spanish multicentre study. Europace

89.

Tsai V, Goldstein MK, Hsia HH, Wang Y, Curtis J, Heidenreich PA et al (2011) Influence of age on perioperative complications among patients undergoing implantable cardioverter-defibrillators for primary prevention in the United States. Circulation: Cardiovascular Quality and Outcomes 4(5):549–556

90.

Parkash R, Stevenson WG, Epstein LM, Maisel WH (2006) Predicting early mortality after implantable defibrillator implantation: a clinical risk score for optimal patient selection. Am Heart J 151(2):397–403PubMedCrossRef

91.

Bilchick KC, Stukenborg GJ, Kamath S, Cheng A (2012) Prediction of mortality in clinical practice for Medicare patients undergoing defibrillator implantation for primary prevention of sudden cardiac death. J Am Coll Cardiol 60(17):1647–1655PubMedPubMedCentralCrossRef

92.

Coresh J, Selvin E, Stevens LA et al (2007) PRevalence of chronic kidney disease in the United States. JAMA 298(17):2038–2047PubMedCrossRef

93.

Garg AX, Clark WF, Haynes RB, House AA (2002) Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int 61(4):1486–1494PubMedCrossRef

94.

Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J (2007) High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 13(6):422–430PubMedCrossRef

95.

Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA et al (2004) The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 44(8):1587–1592PubMedCrossRef

96.

McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW (2004) Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109(8):1004–1009PubMedCrossRef

97.

Stack AG, Bloembergen WE (2001) A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. Am J Kidney Dis 38(5):992–1000PubMedCrossRef

98.

Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW (2000) The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35(3):681–689PubMedCrossRef

99.

US Renal Data System (2006) USRDS 2006 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases

100.

Goldenberg I, Moss AJ, McNitt S, Zareba W, Andrews ML, Hall WJ et al (2006) Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. Am J Cardiol 98(4):485–490PubMedCrossRef

101.

Hager CS, Jain S, Blackwell J, Culp B, Song J, Chiles CD (2010) Effect of renal function on survival after implantable cardioverter defibrillator placement. Am J Cardiol 106(9):1297–1300PubMedCrossRef

102.

Charytan DM, Patrick AR, Liu J, Setoguchi S, Herzog CA, Brookhart MA et al (2011) Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. Am J Kidney Dis 58(3):409–417PubMedCrossRef

103.

Bardy GH, Smith WM, Hood MA, Crozier IG, Melton IC, Jordaens L et al (2010) An entirely subcutaneous implantable cardioverter–defibrillator. N Engl J Med 363(1):36–44PubMedCrossRef

104.

El-Chami MF, Levy M, Kelli HM, Casey M, Hoskins MH, Goyal A et al (2015) Outcome of subcutaneous implantable cardioverter defibrillator implantation in patients with end-stage renal disease on dialysis. J Cardiovasc Electrophysiol 26(8):900–904PubMedCrossRef

105.

Wong MCG, Kalman JM, Pedagogos E, Toussaint N, Vohra JK, Sparks PB et al (2015) Bradycardia and asystole is the predominant mechanism of sudden cardiac death in patients with chronic kidney disease. J Am Coll Cardiol 65(12):1263–1265PubMedCrossRef

106.

Theuns DAMJ, Smith T, Hunink MGM, Bardy GH, Jordaens L (2010) Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. Europace 12(11):1564–1570PubMedPubMedCentralCrossRef

107.

Uhlig K, Balk EM, Earley A, Persson R, Garlitski AC, Chen M, et al. Assessment on implantable defibrillators and the evidence for primary prevention of sudden cardiac death. Evidence Report/Technology Assessment. 2013 Jun 26 of Sudden Cardiac Death. Report No

108.

Hammill SC, Kremers MS, Stevenson LW, Heidenreich PA, Lang CM, Curtis JP et al (2010) Review of the registry’s fourth year, incorporating lead data and pediatric ICD procedures, and use as a national performance measure. Heart Rhythm 7(9):1340–1345PubMedCrossRef

109.

Chen C-Y, Stevenson LW, Stewart GC, Seeger JD, Williams L, Jalbert JJ et al (2013) Impact of baseline heart failure burden on post-implantable cardioverter-defibrillator mortality among Medicare beneficiaries. J Am Coll Cardiol 61(21):2142–2150PubMedCrossRef

110.

Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJV, Granger CB et al (2007) Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116(13):1482–1487PubMedCrossRef

111.

Sanders GD, Hlatky MA, Owens DK (2005) Cost-effectiveness of implantable cardioverter–defibrillators. N Engl J Med 353(14):1471–1480PubMedCrossRef

112.

Colquitt JL, Mendes D, Clegg AJ, Harris P, Cooper K, Picot J, et al. (2014) Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation. Health Technol Assess. 18(56)

113.

Landolina M, Gasparini M, Lunati M, Iacopino S, Boriani G, Bonanno C, et al. (2011) Long-term complications related to biventricular defibrillator implantation. Rate of Surgical Revisions and Impact on Survival: Insights From the Italian ClinicalService Database. 123(22):2526–2535

Title: Prophylactic implantable cardioverter defibrillator in heart failure: the growing evidence for all or Primum non nocere for some?
Authors: Khang-Li Looi
Nigel Lever
Anthony Tang
Sharad Agarwal
Publication date: 01-05-2017
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 3/2017
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-017-9602-y

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prophylactic implantable cardioverter defibrillator in heart failure: the growing evidence for all or Primum non nocere for some?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

Left ventricular strain and twisting in heart failure with preserved ejection fraction: an updated review

A multidimensional sight on cardiac failure: uncovered from structural to molecular level

The mechanisms of air pollution and particulate matter in cardiovascular diseases

Heart transplantation in cardiac amyloidosis

Phosphate imbalance in patients with heart failure

Influenza infection and heart failure—vaccination may change heart failure prognosis?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page